Author: Argüelles-Arias, Federico; Fernández Ãlvarez, Paula; Castro Laria, Luisa; Maldonado Pérez, MarÃa Belén; Belvis Jiménez, MarÃa; Merino-Bohórquez, Vicente; Caunedo Ãlvarez, Angel; Calleja Hernández, Miguel Ãngel
Title: Switch to infliximab subcutaneous during SARS-CoV-2 pandemic: preliminary results Cord-id: pi8ythif Document date: 2021_1_1
ID: pi8ythif
Snippet: A new subcutaneous formulation of the infliximab biosimilar CT-P13 has recently been developed for the treatment of inflammatory bowel disease (IBD), providing response rates similar to intravenous treatment. In an effort to limit patient attendance at intravenous infusion centers and to maintain biological treatment during the COVID-19 pandemic, the use of this new formulation was requested. The objective of this observational, retrospective, and descriptive study was to assess CT-P13 efficacy
Document: A new subcutaneous formulation of the infliximab biosimilar CT-P13 has recently been developed for the treatment of inflammatory bowel disease (IBD), providing response rates similar to intravenous treatment. In an effort to limit patient attendance at intravenous infusion centers and to maintain biological treatment during the COVID-19 pandemic, the use of this new formulation was requested. The objective of this observational, retrospective, and descriptive study was to assess CT-P13 efficacy and safety after switching from intravenous to subcutaneous formulation in patients with IBD receiving maintenance therapy. This article shows preliminary results after six months of follow-up.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date